Mydrane

Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide, the active ingredient in Mydrane, is a combination ophthalmic agent presented as a solution for intracameral injection use. It provides intra‑operative pupil dilation and local anesthesia during cataract surgery.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mydrane is used in ophthalmic procedures to achieve rapid pupil dilation and intra‑ocular anesthesia.

Cataract surgery: provides intra‑operative pupil dilation and anesthesia of the anterior segment. Anterior segment surgery: facilitates pupil dilation and reduces intra‑operative discomfort. Intra‑ocular lens implantation: ensures adequate mydriasis and analgesia during lens placement.

Common Side Effects: - Transient ocular pain or discomfort. - Increased intra‑ocular pressure shortly after injection. - Conjunctival hyperemia or redness. - Corneal edema or mild clouding. - Blurred vision lasting a few hours. - Mild anterior chamber reaction.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) requiring emergency care. - Persistent mydriasis lasting beyond the surgical period. - Acute uveitis or intra‑ocular inflammation. - Retinal detachment. - Endophthalmitis (intra‑ocular infection). - Systemic toxicity from lidocaine (e.g., CNS symptoms).

Before using Mydrane, consider the following precautions: - Assess ocular health: ensure no active infection or inflammation. - Avoid in patients with known hypersensitivity to any component. - Monitor intra‑ocular pressure: watch for postoperative spikes. - Use caution in patients with narrow‑angle glaucoma. - Avoid concurrent use of other mydriatic agents unless clinically required. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Mydrane may interact with other medications as follows:

Major Interactions (Avoid): - Systemic alpha‑adrenergic agonists: may cause excessive hypertension. - Other topical mydriatics: risk of prolonged pupil dilation. - Cholinergic antagonists: additive antimuscarinic effect.

Moderate Interactions (Monitor Closely): - Topical NSAIDs: may increase risk of corneal edema. - Beta‑blocker eye drops: monitor intra‑ocular pressure. - Systemic lidocaine: additive local anesthetic effect.